(Q53614466)

16 May 2018

title

Prospective study of men with clinical benign prostatic hyperplasia treated with alfuzosin by general practitioners: 1-year results. (English)

1 reference

16 May 2018

main subject

prostatic hypertrophy

1 reference

Lukacs B

1

1 reference

16 May 2018

Leplège A

series ordinal

2

1 reference

16 May 2018

Thibault P

series ordinal

3

1 reference

16 May 2018

Jardin A

series ordinal

4

1 reference

16 May 2018

language of work or name

English

0 references

publication date

1 November 1996

1 reference

16 May 2018

published in

Urology

1 reference

16 May 2018

volume

48

1 reference

16 May 2018

issue

5

1 reference

16 May 2018

page(s)

731-740

1 reference

16 May 2018

A study of benign prostatic hyperplasia--a challenge to British urology

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2896%2900302-0

7 January 2021

Transurethral prostatectomy: immediate and postoperative complications. A cooperative study of 13 participating institutions evaluating 3,885 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2896%2900302-0

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2896%2900302-0

7 January 2021

Differences in outcome of transurethral resection of the prostate for benign prostatic hypertrophy between three diagnostic categories

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2896%2900302-0

7 January 2021

Transurethral resection of the prostate for benign prostatic hypertrophy: factors associated with a successful outcome at 1 year

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2896%2900302-0

7 January 2021

Long-term quality of life in patients with benign prostatic hypertrophy: preliminary results of a cohort survey of 7,093 patients treated with an alpha-1-adrenergic blocker, alfuzosin. QOL BPH Study Group in General Practice.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2896%2900302-0

7 January 2021

Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2896%2900302-0

7 January 2021

Alfuzosin for treatment of benign prostatic hypertrophy. The BPH-ALF Group

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2896%2900302-0

7 January 2021

Urinary flow rates in patients with benign prostatic hypertrophy following treatment with alfuzosin. DUALF Group

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2896%2900302-0

7 January 2021

Long-term treatment of benign prostatic hyperplasia with alfuzosin: a 24-30 month survey. BPHALF Group

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2896%2900302-0

7 January 2021

The state of outcome research: are we on target?

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2896%2900302-0

7 January 2021

A comparison of transurethral surgery with watchful waiting for moderate symptoms of benign prostatic hyperplasia. The Veterans Affairs Cooperative Study Group on Transurethral Resection of the Prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2896%2900302-0

7 January 2021

The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2896%2900302-0

7 January 2021

Correlation of the American Urological Association symptom index with self-administered versions of the Madsen-Iversen, Boyarsky and Maine Medical Assessment Program symptom indexes. Measurement Committee of the American Urological Association

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2896%2900302-0

7 January 2021

A comparison of quality of life with patient reported symptoms and objective findings in men with benign prostatic hyperplasia. The Department of Veterans Affairs Cooperative Study of transurethral resection for benign prostatic hyperplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2896%2900302-0

7 January 2021

Long-term treatment of benign prostatic hyperplasia with alfuzosin: a 12-18 month assessment. BPHALF Group

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2896%2900302-0

7 January 2021

Urinary symptoms in the community: how bothersome are they?

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2896%2900302-0

7 January 2021

Methods for quality-of-life studies

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2896%2900302-0

7 January 2021

10.1016/S0090-4295(96)00302-0

Identifiers

DOI

1 reference

16 May 2018

1 reference

16 May 2018